High dose immunoglobulin (IVIG) may reduce the incidence of Langerhans cell histiocytosis (LCH)-associated central nervous system involvement

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 5, 2009, Pages 380-386

  Imashuku, Shinsaku ^a  

^a Takasago seibu Hospital   (Japan)

Author keywords

Central nervous system; Diabetes insipidus; Intravenous immunoglobulin; Langerhans cell histiocytosis; Neurodegenerative disease

Indexed keywords

CLADRIBINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TALTIRELIN; VINBLASTINE; VINCRISTINE;

DEGENERATIVE DISEASE; DIABETES INSIPIDUS; DRUG MEGADOSE; HIGH RISK PATIENT; HISTIOCYTOSIS X; HUMAN; IMMUNOTHERAPY; INCIDENCE; NEUROLOGICAL COMPLICATION; PROPHYLAXIS; REVIEW; NERVE DEGENERATION;

DIABETES INSIPIDUS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES;

EID: 73949104485     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789541970     Document Type: Review

References (75)

1. Donadieu, J, Egeler, R.M.; Pritchard, J. In Histiocytic Disorders of Children and Adults; Weitzman, S.; Egeler, R.M., Eds.; Cambridge University Press: England, 2005, pp. 95-129.
2. Dunger, D.B.; Broadbent, V.; Yeoman, E.; Seckl, J.R.; Lightman, S.L.; Grant, D.B.; Pritchard, J. The frequency and natural history of diabetes insipidus in children with Langerhans cell histiocytosis. N. Engl. J. Med., 1989, 321, 1157-1162.
3. McLelland, J.; Broadbent, V.; Yeomans, E.; Malone, M.; Pritchard, J. Langerhans cell histiocytosis: the case for conservative treatment. Arch. Dis. Child., 1990, 65, 301-303.
4. Haupt, R.; Nanduri, V.; Calevo, M.G.; Bernstrand, C.; Braier, J.L.; Broadbent, V.; Rey, G.; McClain, K.L.; Janka-Schaub, G.; Egeler, R.M. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr. Blood Cancer, 2004, 42, 438-444.
5. Poe, L.B.; Dubowy, R.L.; Hochhauser, L.; Collins, G.H.; Crosley, C.J.; Kanzer, M.D.; Oliphant, M.; Hodge, C.J., Jr. Demyelinating and gliotic cerebellar lesions in Langerhans cell histiocytosis. AJNR Am. J. Neuroradiol., 1994, 15, 1921-1928.
6. Goldberg-Stern, H.; Weitz, R.; Zaizov, R.; Gornish, M.; Gadoth, N. Progressive spinocerebellar degeneration "plus" associated with Langerhans cell histiocytosis: a new paraneoplastic syndrome? J. Neurol. Neurosurg. Psychiatr., 1995, 58, 180-183.
7. Cervera, A.; Madero, L.; Garcia Penas, J.J.; Diaz, M.A.; Gutierrez-Solana, L.G.; Benito, A.; Ruiz-Falcó, M.L.; Villa, M. CNS sequelae in Langerhans cell histiocytosis: progressive spinocerebellar degeneration as a late manifestation of the disease. Pediatr. Hematol. Oncol., 1997, 14, 577-584.
8. Barthez, M.A.; Araujo, E.; Donadieu, J. Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study. J. Child. Neurol., 2000, 15, 150-156.
9. van de Warrenburg, B.P.; van der Heijden, H.F.; Pieters, G.; Kremer, H.P. Langerhans' cell histiocytosis presenting with progressive spinocerebellar ataxia. J. Neurol., 2003, 250, 1112-1114.
10. Grois, N.; Barkovich, A.J.; Rosenau, W.; Ablin, A.R. Central nervous system disease associated with Langerhans' cell histiocytosis. Am. J. Pediatr. Hematol. Oncol., 1993, 15, 245-254.
11. Grois, N.G.; Favara, B.E.; Mostbeck, G.H.; Prayer, D. Central nervous system disease in Langerhans cell histiocytosis. Hematol. Oncol. Clin. North Am., 1998, 12, 287-305.
12. Grois, N.; Prayer, D.; Prosch, H.; Lassmann, H.; CNS LCH Cooperative Group. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain, 2005, 128(Pt 4), 829-838.
13. Prayer, D.; Grois, N.; Prosch, H.; Gadner, H.; Barkovich, A.J. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am. J. Neuroradiol., 2004, 25, 880-891.
14. Martin-Duverneuil, N.; Idbaih, A.; Hoang-Xuan, K.; Donadieu, J.; Genereau, T.; Guillevin, R.; Chiras, J.; French Langerhans Cell Histiocytosis Study Group. MRI features of neurodegenerative Langerhans cell histiocytosis. Eur. Radiol., 2006, 16, 2074-2082.
15. Grois, N.; Posch, H.; Lassmann, H.; Prayer, D. In Histiocytic Disorders of Children and Adults; Weitzman, S.; Egeler, R.M.; Eds. Cambridge University Press: England, 2005, pp. 208-228.
16. Grois, N.; Potschger, U.; Prosch, H.; Minkov, M.; Arico, M.; Braier, J.; Henter, J.I.; Janka-Schaub, G.; Ladisch, S.; Ritter, J.; Steiner, M.; Unger, E.; Gadner, H. DALHX- and LCH I and II Study Committee. DALHX- and LCH I and II Study Committee. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr. Blood Cancer, 2006, 46, 228-233.
17. Egeler, R.M.; Favara, B.E.; van Meurs, M.; Laman, J.D.; Claassen, E. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood, 1999, 94, 4195-4201.
18. De Filippi, P.; Badulli, C.; Cuccia, M.; De Silvestri, A.; Dametto, E.; Pasi, A.; Garaventa, A.; del Prever, A.B.; Todesco, A.; Trizzino, A.; Danesino, C.; Martinetti, M.; Aricò, M. Specific polymorphisms of cytokine genes are associated with different risks to develop single-system or multi-system childhood Langerhans cell histiocytosis. Br. J. Haematol., 2006, 132, 784-787.
19. Chan, A.; Papadimitriou, C.; Graf, W.; Toyka, K.V.; Gold, R. Effects of poluclonal immunoglobulins and other immunomodulatory agents on microglial phagocytosis of apoptotic inflammatory T-cells. J. Neuroimmunol., 2003, 135(1-2), 161-165.
20. Janke, A.D.; Yong, V.W. Impact on the interaction between activated T cells and microglia. Neurol. Res., 2006, 28, 270-274.
21. Stangel, M.; Compston, A. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J. Neuroimmunol., 2001, 112, 63-71.
22. Lahey, E. Histiocytosis X-an analysis of prognostic factors. J. Pediatr., 1975, 87, 184-189.
23. Minkov, M.; Grois, N.; Heitger, A.; Pötschger, U.; Westermeier, T.; Gadner, H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin. Padiatr., 2000, 212, 139-144.
24. Gadner, H.; Grois, N.; Arico, M.; Broadbent, V.; Ceci, A.; Jakobson, A.; Komp, D.; Michaelis, J.; Nicholson, S.; Pötschger, U.; Pritchard, J.; Ladisch, S.; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J. Pediatr., 2001, 138, 728-734.
25. Morimoto, A.; Ikushima, S.; Kinugawa, N.; Ishii, E.; Kohdera, U.; Sako, M.; Fujimoto, J.; Bessho, F.; Horibe, K.; Tsunematsu, Y.; Imashuku, S.; Japan Langerhans Cell Histiocytosis Study Group. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer, 2006, 107, 613-619.
26. Gadner, H.; Ladisch, S. In Histiocytic Disorders of Children and Adults; Weitzman, S.; Egeler, R.M., Eds.; Cambridge University Press: England, 2005, pp. 229-253.
27. Stine, K.C.; Saylors, R.L.; Saccente, S.; McClain, K.L.; Becton, D.L. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr. Blood Cancer, 2004, 43, 81-84.
28. Bernard, F.; Thomas, C.; Bertrand, Y.; Munzer, M.; Landman, P.J.; Ouache, M.; Colin, V.M.; Perel, Y.; Chastagner, P.; Vermylen, C.; Donadieu, J. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur. J. Cancer, 2005, 41, 2682-2689.
29. Sato, Y.; Ikeda, Y.; Ito, E.; Miyano, T.; Kawauchi, K.; Yokoyama, M.; Kamata, Y. Histiocytosis X: successful treatment with recombinant interferon-alpha A. Acta Paediatr. Jpn., 1990, 32, 151-154.
30. Chang, S.E.; Koh, G.J.; Choi, J.H.; Lee, K.H.; Sung, K.J.; Moon, K.C.; Koh, J.K. Widespread skin-limited adult Langerhans cell histiocytosis: long-term follow-up with good response to interferon alpha. Clin. Exp. Dermatol., 2002, 27, 135-137.
31. Arico, M.; Colella, R.; Conter, V.; Indolfi, P.; Pession, A.; Santoro, N.; Burgio, G.R. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med. Pediatr. Oncol., 1995, 25, 12-16.
32. Zeller, B.; Storm-Mathisen, I.; Smevik, B.; Lie, S.O. Multisystem Langerhans-cell histiocytosis with life-threatening pulmonary involvement-good response to cyclosporine A. Med. Pediatr. Oncol., 2000, 35, 438-442.
33. Minkov, M.; Grois, N.; Broadbent, V.; Ceci, A.; Jakobson, A.; Ladisch, S. Cyclosporine A therapy for multisystem langerhans cell histiocytosis. Med. Pediatr. Oncol., 1999, 33, 482-485.
34. Padula, A.; Medeiros, L.J.; Silva, E.G.; Deavers, M.T. Isolated vulvar Langerhans cell histiocytosis: report of two cases. Int. J. Gynecol. Pathol., 2004, 23, 278-283.
35. Montero, A.J.; Diaz-Montero, C.M.; Malpica, A.; Ramirez, P.T.; Kavanagh, J.J. Langerhans cell histiocytosis of the female genital tract: a literature review. Int. J. Gynecol. Cancer, 2003, 13, 381-388.
36. Farran, R.P.; Zaretski, E.; Egeler, R.M. Treatment of Langerhans cell histiocytosis with pamidronate. J. Pediatr. Hematol. Oncol., 2001, 23, 54-56.
37. Kamizono, J.; Okada, Y.; Shirahata, A.; Tanaka, Y. Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis. J. Bone Miner. Res., 2002, 17, 1926-1928.
38. Munn, S.E.; Olliver, L.; Broadbent, V.; Pritchard, J. Use of indomethacin in Langerhans cell histiocytosis. Med. Pediatr. Oncol., 1999, 32, 247-249.
39. Büchler, T.; Cervinek, L.; Belohlavek, O.; Kantorova, I.; Mechl, M.; Nebesky, T.; Vorlicek, J.; Adam, Z. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr. Blood Cancer, 2005, 44, 286-288.
40. Dhall, G.; Finlay, J.L.; Dunkel, I.J.; Ettinger, L.J.; Kellie, S.J.; Allen, J.C.; Egeler, R.M.; Arceci, R.J. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr. Blood Cancer, 2008, 50, 72-79.
41. Ottaviano, F.; Finlay, J.L. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J. Pediatr. Hematol. Oncol., 2003, 25, 575-577.
42. Grois, N.; Prosch, H.; Waldhauser, F.; Minkov, M.; Strasser, G.; Steiner, M.; Unger, E.; Prayer, D. Pineal gland abnormalities in Langerhans cell histiocytosis. Pediatr. Blood Cancer, 2004, 43, 261-266.
43. Idbaih, A.; Donadieu, J.; Barthez, M.A.; Geissmann, F.; Bertrand, Y.; Hermine, O.; Brugières, L.; Genereau, T.; Thomas, C.; Hoang-Xuan, K. Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr. Blood Cancer, 2004, 43, 55-58.
44. Imashuku, S.; Okazaki, N.A.; Nakayama, M.; Fujita, N.; Fukuyama, T.; Koike, K.; Minato, T.; Kobayashi, R.; Morimoto, A.; Japan LCH Study Group. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr. Blood Cancer, 2008, 50, 308-311.
45. st Annual Meeting Abstract of Histiocyte Society, 2005, p. 35.
46. Gern, J.E. Antiinflammatory activity of IVIG mediated through the inhibitory Fc receptor. Pediatrics, 2002, 110, 467-468.
47. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med., 2007, 204, 11-15.
48. Bavry, J.; Thirion, M.; Misra, N.; Thorenoor, N.; Delignat, S.; Lacroix-Desmazes, S.; Bellon, B.; Kaveri, S.; Kazatchkine, M.D. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol. Sci., 2003, 24, S217-S221.
49. Kessel, A.; Ammuri, H.; Peri, R.; Pavlotzky, E.R.; Blank, M.; Shoenfeld, Y.; Toubi, E. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol., 2007, 179, 5571-5575.
50. Ephrem, A.; Chamat, S.; Miquel, C.; Fisson, S.; Mouthon, L.; Caligiuri, G.; Delignat, S.; Elluru, S.; Bayry, J.; Lacroix-Desmazes, S.; Cohen, J.L.; Salomon, B.L.; Kazatchkine, M.D.; Kaveri, S.V.; Misra, N. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 2008, 111, 715-722.
51. Tha-In, T.; Metselaar, H.J.; Tilanus, H.W.; Groothuismink, Z.M.; Kuipers, E.J.; de Man, R.A.; Kwekkeboom, J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood, 2007,110, 3253-3262.
52. Gürcan, H.M.; Ahmed, A.R. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann. Pharmacother., 2007, 41, 812-823.
53. Leung, D.Y. The immunologic effects of IVIG in Kawasaki disease. Int. Rev. Immunol., 1989, 5, 197-202.
54. Newburger, J.W.; Takahashi, M.; Beiser, A.S.; Burns, J.C.; Bastian, J.; Chung, K.J.; Colan, S.D.; Duffy, C.E.; Fulton, D.R.; Glode, M.P.; Mason, W.H.; Meissner, H.; Cody, R.A.H.; Reddy, V.; Sundel, R.P.; Melish, M.E.; Rosen, F.S. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med., 1991, 324, 1633-1639.
55. Sakata, K.; Hamaoka, K.; Ozawa, S.; Niboshi, A.; Yoshihara, T.; Nishiki, T.; Nakagawa, Y.; Kazuta, K.; Morimoto, Y.; Kamiya, Y.; Yamamoto, T.; Horii, Y.; Kido, S. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur. J. Pediatr., 2007, 166, 565-571.
56. Bierling, P.; Godeau, B. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Hum. Immunol., 2005, 66, 387-394.
57. Freeman, B.; Bathore, M.H.; Salman, E.; Joyce, M.J.; Pitel, P. Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome. J. Pediatr., 1993, 123, 479-481.
58. Spickett, G.P.; Zhang, J.G.; Green, T.; Shrimankar, J. Granulomatous disease in common variable immunodeficiency: effect on immunoglobulin replacement therapy and response to steroids and splenectomy. J. Clin. Pathol., 1996, 49, 431-434.
59. Fakhouri, F.; Robino, C.; Lemaire, M.; Droz, D.; Noël, L.H.; Knebelmann, B.; Lesavre, P. Granulomatous renal disease in a patient with common variable immunodeficiency. Am. J. Kidney Dis., 2001, 38, E7.
60. Taniguchi, M.; Tsurikisawa, N.; Higashi, N.; Saito, H.; Mita, H.; Mori, A.; Sakakibara, H.; Akiyama, K. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol. Int., 2007, 56, 97-103.
61. Abdel-Naser, M.B.; Wollina, U.; El Hefnawi, M.A.; Habib, M.A.; El Okby, M. Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency.?? J. Drugs Dermatol., 2006, 5, 370-372.
62. Yalavarthy, U.C.; Panda, M. A middle-aged female with recurrent sinopulmonary infections: a case report. J. Med. Case Rep., 2008, 2, 117.
63. Achiron, A.; Kishner, I.; Sarova-Pinhas, I.; Raz, H.; Faibel, M.; Stern, Y.; Lavie, M.; Gurevich, M.; Dolev, M.; Magalashvili, D.; Barak, Y. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol., 2004, 61, 1515-1520.
64. Jorgensen, S.H.; Jensen, P.E.; Laursen, H.; Sorensen, P.S. Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol. Res., 2005, 27, 591-597.
65. Durelli, L.; Isoardo, G. High-dose intravenous immunoglobulin treatment of multiple sclerosis. Neurol. Sci., 2002, 23(suppl 1), S39-S48.
66. Izumida, M.; Sano, H.; Okano, T.; Nitta, K.; Takayama, C.; Sugawara, S.; Watanabe, O.; Itakura, K.; Shimizu, H.; Ogawa, Y. A case report of intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. J. Jpn. Pediatr. Soc., 2002, 106, 891-895.
67. Kalanie, H.; Tabatabai, S.S. Combined Immunoglobulin and Azathioprine in Multiple Sclerosis. Eur. Neurol., 1998, 39, 178-181.
68. Imashuku, S.; Shioda, Y.; Kobayashi, R.; Hosoi, G.; Fujino, H.; Seto, S.; Wakita, H.; Oka, A.; Okazaki, N.; Fujita, N.; Minato, T.; Koike, K.; Tsunematsu, Y.; Morimoto, A.; Japan LCH Study Group (JLSG). Neurodegenerative Central Nervous System Disease as Late Sequelae of Langerhans cell histiocytosis; JLSG Report. Haematologica, 2008, 93, 615-618.
69. st Annual Meeting of Histiocyte Society, 2005, abstract p. 28.
70. Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 1983, 33, 1444-1452.
71. Trouillas, P.; Takayanagi, T.; Hallett, M.; Currier, R.D.; Subramony, S.H.; Wessel, K.; Bryer, A.; Diener, H.C.; Massaquoi, S.; Gomez, C.M.; Coutinho, P.; Ben Hamida, M.; Campanella, G.; Filla, A.; Schut, L.; Timann, D.; Honnorat, J.; Nighoghossian, N.; Manyam, B. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J. Neurol. Sci., 1997, 145, 205-211.
72. Fazekas, F.; Sorensen, P.S.; Filippi, M.; Ropele, S.; Lin, X.; Koelmel, H.W.; Fernandez, O.; Pozzilli, C.; O'Connor, P.; Enriquez, M.M.; Hommes, O.R.; ESIMS. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult. Scler., 2005, 11, 433-440.
73. Whitsett, S.F.; Kneppers, K.; Coppes, M.J.; Egeler, R.M. Neuropsychologic deficits in children with Langerhans cell histiocytosis. Med. Pediatr. Oncol., 1999, 33, 486-492.
74. Mittheisz, E.; Seidl, R.; Prayer, D.; Waldenmair, M.; Neophytou, B.; Pötschger, U.; Minkov, M.; Steiner, M.; Prosch, H.; Wnorowski, M.; Gadner, H.; Grois, N. Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr. Blood Cancer, 2007, 48, 50-56.
75. Tsai, M.H.; Huang, Y.C.; Yen, M.H.; Li, C.C.; Chiu, C.H.; Lin, P.Y.; Lin, T.Y.; Chang, L.Y. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. J. Pediatr., 2006, 148, 38-43.